Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guanxinning tablet for coronary artery disease after PCI
ChiCTR-IIR-17010688Phase 4Recruiting
- Sponsor
- Xiyuan Hospital
- Start
- Aug 2016
- Countries
- 1
01
Overview
Phase 4, open-label trial of Guanxinning in coronary arteriosclerosis (2 arms), sponsored by Xiyuan Hospital. Primary endpoint: Composite major adverse cardiovascular events. Started Aug 2016; status: recruiting.
02
Drugs
Guanxinning
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR-IIR-17010688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-17010688.